We use cookies to improve the technical capabilities of the service and to analyze user activity. You can learn more about cookies in our Privacy Policy (personal data processing) By clicking “Accept”, you agree to the conditions for the processing of cookies and other analytics information.
Accept
GemoVis
A new‑type local hemostatic agent for highly effective control and stopping of bleeding.
Hemostatic gel “Gemovis” stops bleeding over a wide wound area. Time to achieve hemostasis is less than 60 seconds.
The use of “Gemovis” reduces blood loss by more than three times. It is capable of controlling bleeding from major vessels and can be used as an alternative to tourniquet application.
Hemostatic gel “Gemovis” has antiseptic effect to stimulate reparative processes. Effective for preventing infections, which are common complications of injuries sustained in field conditions, due to its antiseptic activity.
Hemostatic gel “Gemovis” is convenient to use on complex wound surfaces, spreads over the entire wound area and prevents recurrent bleeding. The Gemovis gel form is convenient for hemostasis of wounds with complex configuration, compared to hemostatic agents in powder and non‑woven‑bandage forms.
Hemostatic gel “Gemovis” can be universally used on any type of wounds and does not require wound bed preparation or drying. After reliable hemostasis has been achieved the gel does not need to be removed from the wound.
Feature
LHV Gemovis gel
LHV in the form of powders and granules based on chitosan and kaolin
LHV in the form of bandages based on chitosan and kaolin
LHV in the form of collagen sponges
Time to complete hemostasis in severe bleeding
1 minute
3-5 minutes
3-5 minutes
3-5 minutes
Significant reduction in the volume of blood loss while ensuring isolation of the damaged or injured surface
The ability to stop massive bleeding from narrow, deep wounds with a complex wound channel shape
No further removal from the wound area is required
Additional antiseptic activity to prevent wound infection and accelerate its healing
Possibility of biodegradation in the wound
Possibility of introducing a hemostatic agent into a small wound (from 3 mm in diameter)
Surgical application without long-term wound tamponade
Effectiveness of use in cases of multiple shrapnel wounds (example: resulting from mine blast injuries)
Possibility of independent use (without help from others)
«Every drop matters»
Bleeding is one of the most serious complications in various injuries, wounds, traumas, and surgical interventions.
High‑quality hemostasis control plays a crucial role in reducing overall blood loss and preventing recurrent bleeding episodes.
The problem of temporary control of external hemorrhage is one of the most important not only in military medicine but also in civil emergency medicine.
The use of hemostatic gel Gemovis allows stabilization and preparation of injured patients for evacuation, avoiding massive blood loss.
General and dental surgery
More details on the use of “Gemovis” in surgical practice.
Local Hemostatic Agent (LHA) “Gemovis.” Sterile, single‑use hemostatic gel for highly effective and targeted control of bleeding of various intensity. In modern medicine there is a concept of the “golden hour”—the time window after injury or trauma during which prompt medical care has the greatest chance to save the patient. However, in field conditions rapid evacuation to hospital is not always possible. In this regard the main task is to extend the “golden hour” as long as possible through proper actions, so that the patient can reach the operating table before irreversible consequences occur.
Functional purpose of LHA “Gemovis”: control of massive bleeding, mainly at the pre‑hospital stage, by activating the human hemostasis system.
LHA “Gemovis” provides external isolation of the injured surface, helps prevent septic complications and wound infection during bleeding, and has a pronounced hemostatic effect when major vessels are injured. It can be used as an alternative to the potentially unsafe procedure of tourniquet application (especially for injuries of proximal limb segments, neck, and pelvis). The mechanism of action is based on deep penetration into the wound area and intensive local hemoconcentration.
The gel form of LHA “Gemovis” is convenient for control of combined bleeding from wounds with complex configuration, which distinguishes it from the main types of hemostatic agents in the form of powders, granules, and bandages. It is convenient for providing targeted care or self‑aid in intense, multiple, and mixed bleeding (arterial, venous, capillary).
LHA “Gemovis” exerts a complex effect:
rapidly stops massive, intense bleeding;
prevents wound inflammation, suppresses development of wound infection, and accelerates wound healing.
LHA “Gemovis” is universal and simple to use:
effective on any type of injuries;
does not require preparation or drying of the wound bed;
shows high adhesion to the wound surface;
does not need to be removed from the wound.
LHA “Gemovis” meets all modern requirements for agents of this group, both in tactical medicine and in general surgical practice.